World Health Organization
-
A new article published in The Lancet is arguing against broadly administering COVID-19 vaccine booster shots. The article is co-authored by two of the FDA's top vaccine advisors, both of whom recently announced they were stepping down from their positions.
-
The director of the WHO has said he is “appalled” at the extent of vaccine inequity spreading across the world. Global vaccine-sharing initiative COVAX has reported it is falling short of its distribution milestones as wealthy countries take most doses.
-
For the first time in several months the World Health Organization has added another SARS-CoV-2 variant to its official tracking list. Given the Greek Alphabet letter Mu, this newly defined “variant of interest” has been detected in 40 countries.
-
Over five billion COVID-19 vaccine doses have now been administered around the world. This milestone comes eight months after vaccinations commenced, however, the World Health Organization has expressed concern over the disparity in vaccine distribution.
-
The WHO is launching a large-scale global clinical trial testing whether a trio of pre-existing drugs can treat those hospitalized with severe COVID-19. The project serves as the new phase of WHO’s Solidarity project.
-
The WHO has called for a global halt on vaccine boosters until at least the end of September to prioritize supplies for poorer nations with unvaccinated vulnerable populations. The goal is to have 10 percent of every country vaccinated within two months.
-
In the space of a few months the Delta variant has become the dominant strain of SARS-CoV-2 around the world. But what comes after Delta, how are new variants being named, and what is a "Variant of Concern"?
-
With the WHO warning Delta could be just the beginning of SARS-CoV-2's evolution, a modeling study indicates high levels of virus transmission in conjunction with middling vaccination rates is an ideal scenario for new variants to emerge.
-
BioNTech, the pioneering mRNA company responsible for one of the world’s first COVID-19 vaccines, is now looking to develop an mRNA malaria vaccine. Working with the World Health Organization the company hopes to begin human trials sometime next year.
-
When will COVID-19 vaccine booster shots be necessary? Pfizer claims a third booster of its vaccine may be needed six to 12 months after vaccination but not everyone is convinced, with new research finding mRNA vaccines may offer years of protection.
-
Results from a trial testing a new malaria vaccine have revealed an impressive 77 percent efficacy, higher than any prior vaccine trialled. The vaccine is the first to reach a WHO goal of at least 75 percent efficacy and a larger trial is now underway.
-
The World Health Organization is rapidly responding to a pair of new Ebola outbreaks in Africa. The two unrelated outbreaks, in Guinea and the Democratic Republic of Congo, have both appeared in locations previously connected to Ebola flare-ups.
Load More